通过多种策略缩放胰岛素产生细胞
Jinhyuk Choi1, Fritz Cayabyab1, Harvey Perez1
1The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Endocrinology and metabolism (Seoul, Korea)
|April 4, 2024
概括
从干细胞生成胰岛素生成β细胞为治疗胰岛素依赖性糖尿病 (IDDM) 提供了一个有前途的替代方案. 在扩大这些细胞扩张技术以广泛临床使用方面,仍然存在挑战.
科学领域:
- 再生医学是一种再生医学.
- 干细胞生物学 干细胞生物学
- 内分泌学 在内分泌学.
背景情况:
- 全基性胰腺小岛细胞疗法是胰岛素依赖糖尿病 (IDDM) 的关键进展,但面临着供体稀缺和免疫抑制问题.
- 人类诱导的多能干细胞 (hiPSCs) 为产生功能性胰岛素生成β细胞提供了一种可再生的来源.
- 胰腺原生细胞和成熟β细胞的直接扩张绕过了漫长的分化协议.
研究的目的:
- 批判性地评估来自干细胞的胰腺β细胞的当前扩张技术.
- 确定优化和扩展这些细胞疗法用于IDDM治疗的关键挑战和机会.
主要方法:
- 对扩张胰腺原生细胞和成熟β细胞的新方法的审查和分析.
- 评估利用人类诱导的多能干细胞用于β细胞生成的技术.
- 评估当前方法的可扩展性,可重复性,成本效益和后勤因素.
主要成果:
- 人类诱导的多能干细胞为产生合成,功能性胰岛素生产β细胞提供了可行的资源.
- 直接扩展方法为传统的差异化协议提供了更快的替代方案.
- 在实现这些先进疗法的实际可重复性和可扩展性方面存在重大挑战.
结论:
- 来自干细胞的β细胞在治疗IDDM方面具有巨大的潜力,为传统的小岛移植提供了替代方案.
- 细胞扩张技术的优化和扩展对于临床翻译至关重要.
- 解决成本效益和后勤障碍对于这些创新疗法的广泛采用至关重要.
相关概念视频
01:24Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
01:25Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
01:16Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K